GET IT RIGHT THE FIRST TIME WITH

AVANCE

CLINICAL

Full Service CRO

With strong co-existing relationships with all Phase 1 units across Australia.

Highly Experienced Team

Supporting our global client portfolio with over 20 years’ experience.

Globally accepted DATA

World class reputation for accuracy, precision and quality data sets.

THE AUSTRALIAN Advantage

The Australian Regulatory Framework is the fastest in the world for undertaking early phase clinical trials.

FULL SERVICE CRO

Backed by a proven network of leading trial sites across Australia and New Zealand.

HIGHLY EXPERIENCED TEAM

A track-record of delivering for a global client-base for more than 20 years.

GLOBALLY ACCEPTED DATA

World-class reputation for accuracy, precision and quality data sets.

THE AUSTRALIAN ADVANTAGE

Australia’s regulatory framework is the fastest in the world for early-phase clinical trials.

eCLINICAL SOLUTIONS

Deploy the latest solutions to maximise the value of your study data and deliver real-time visibility on your study progress.

Latest News & Events

View All

Avance Clinical Releases Industry Survey Results at BIO Korea 2021 – Data Quality the Top Criteria for Selecting a CRO

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical shared results of a recent industry survey conducted by the company that found data quality to be the most important criteria for selecting a CRO for Phase ll studies in Australia.

Results from the survey found 63.64% of respondents selected data quality as the Key operational consideration when planning Phase II, followed by access to patients, then CRO therapeutic area expertise, cost, and access to KOLs.

Avance Clinical Wins Excellence in Business Award 2021

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical has won the Fast Movers SA Excellence in Business Award 2021 sponsored by international accounting and business advisory firm BDO.

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).

This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).

Avance Clinical Invited to Present “Decentralized Trials – No Going Back” for Oracle Health Sciences Connect

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Avance Clinical CEO Yvonne Lungershausen, shared the company’s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success.
Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.

Avance Clinical Featured in Endpoints News

A year ago Australia was largely known predominantly for its early phase capabilities. However much has changed with Australia becoming the “COVID-19 free” envy of the world. Australia regularly records zero new daily COVID-19 cases, backed by the world’s leading contact tracing systems, mandatory travel quarantine, and strict borders.

News: Avance Clinical Adds Oracle Argus Safety and Pharmacovigilance Platform to its Clinical Technology Solutions

“We are excited to welcome Avance Clinical to our global community of Argus customers,” said Bruce Palsulich, Vice President, Safety Product Strategy, Oracle Health Sciences.

“Argus provides proven compliance with continuously changing worldwide regulations, and its built-in automations, integrations, and usability significantly reduce manual work and maximize efficiency. We are pleased that Avance Clinical has chosen to standardize on Argus for safety case management.”

AUSTRALIA & ASIA-PACIFIC CRO MARKET REPORT: Frost & Sullivan

Avance Clinical has positioned itself as a global leader in early phase clinical trials by developing innovative strategies and approaches to initial phase development. It helps global biotech companies set up clinic and achieve proof of concept faster with a data package that stands up to the scrutiny of global regulators. The company is well […]

News: Avance Clinical Client Atossa Therapeutics Announces Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that client Atossa Therapeutics has announced a positive interim safety assessment from the second cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray.

News: Avance Clinical ‘ClinicReady’ Featured in Endpoints News

Avance Clinical has formed a dedicated scientific and regulatory affairs service, ClinicReady by Avance Clinical, in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.

The highly regarded Avance Clinical scientific and regulatory team, which has been advising biotech clients on their drug development for more than 20 years, is now a dedicated ClinicReady service under the Avance Clinical banner.

News: Jorgen Mould PhD, BSc (Hons) joins Avance Clinical as Scientific Affairs Specialist

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to announce the appointment of Jorgen Mould PhD, BSc (Hons) as Scientific Affairs Specialist
Jorgen has over 23 years of experience in medical research and drug development.

With a passion for developing new treatments for human diseases, Jorgen has worked in positions that span the full spectrum of a drug lifecycle from bench side discovery to post market approval.

News: Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn’s disease.

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Avance Clinical offers end to end services ensuring projects are delivered on time and on budget with embedded quality assurance. Conducted to the highest ethical and regulatory standards and employing stringent Quality Assurance procedures, Avance Clinical customises its approach to meet the specific objectives of each and every client. With extensive experience across all phases of clinical research, complemented with our seamless suite of in-house services we can ensure your trials are delivered on time and on budget.

Small font size.

Normal font size.

Medium font size.

Large font size.

Huge font size.

Avance Clinical

Avance Clinical is a full-service Contract Research Organisation offering a suite of in-house clinical research services. Located in Australia, Avance has sustained an international reputation for delivering high quality clinical trial results across all phases and therapeutic areas of drug development.

With the ability to operate as an efficient multiservice CRO and utilise established networks enabling ease of access to patient populations in both a hospital and clinic setting. Avance Clinical has a demonstrated history of experience in both early and late phase trials.

Clinical Services

Avance Clinical offers end to end services ensuring projects are delivered on time and on budget with embedded quality assurance

Within Asia-Pacific’s highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. The company offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance. Avance Clinical offers a real size match for biotechs that means better mission understandings and stronger customer service compared to some of the larger CROs.

Nidhi Jalali, Analyst Best Practices, Frost & Sullivan

image left
image right
image left

“Avance has sustained an international reputation for delivering high quality clinical trial results across all phases and therapeutic areas of drug development.”

image right
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6

“We aim to give clients unparalleled service to optimise the timely and cost effective completion of projects. It’s as simple as that”

Yvonne Lungershausen,
Chief Executive Officer

Site Initiation Visit (SIV) and Study Start can be achieved in 5 – 6 Weeks.

This means that a Site Initiation Visit (SIV) and Study Start can be achieved in 5 – 6 weeks. The ability to get clinical data quickly allows Sponsors to gain critical Go/No Go information on their product faster than anywhere else in the world.

Working within this robust and efficient framework expedites the process of running a clinical trial.

This means that a Site Initiation Visit (SIV) and Study Start can be achieved in 5 – 6 weeks. The ability to get clinical data quickly allows Sponsors to gain critical Go/No Go information on their product faster than anywhere else in the world.

Meet the team

Glenn Haifer

Chairman

“It has been a great pleasure working with you on this project. Your flexibility, pragmatic approaches and focus on the work has been exceptional. I am looking forward to have the next compound entering the clinic with you.”

Head of drug discover
Pharmaxis Ltd

“Working with the Avance Team has helped us to develop and complete high quality and compliant clinical studies. I especially appreciate their penchant for communication, quality and pragmatism.”

– Sr. Vice President, Regulatory, Quality & Clinical Affairs
Atossa Genetics, Inc.

Contact Us

Level 1, 2 Ann Nelson Drive, Thebarton SA 5031

Phone: +61 8 8159 6388
Fax: +61 8 8159 6348
Email: enquiries@avancecro.com
Web: www.avancecro.com

Office Hours:
Monday to Friday: 8.00 am to 5.30 pm

Content here…